Related references
Note: Only part of the references are listed.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Intratumoral administration of IL2-and TNF-based fusion proteins cures cancer without establishing protective immunity
Barbara Ziffels et al.
IMMUNOTHERAPY (2018)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data
Vanessa Jurtz et al.
JOURNAL OF IMMUNOLOGY (2017)
Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy
Roberto De Luca et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Vinod P. Balachandran et al.
NATURE (2017)
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Marta Luksza et al.
NATURE (2017)
Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
Greta Garrido et al.
FRONTIERS IN PHARMACOLOGY (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA- targeted IL-2 variant- based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein et al.
ONCOIMMUNOLOGY (2017)
Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy
Yosuke Ohno et al.
CANCER SCIENCE (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen
Philipp Probst et al.
CANCER RESEARCH (2017)
Role of isolated limb perfusion with recombinant human tumor necrosis factor and melphalan in locally advanced extremity soft tissue sarcoma
Jens Jakob et al.
CANCER (2016)
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
David Planchard et al.
CLINICAL LUNG CANCER (2016)
Immunocytokines for cancer treatment: past, present and future
Dario Neri et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions
Franziska Bootz et al.
DRUG DISCOVERY TODAY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format
Sina Fellermeier et al.
OncoImmunology (2016)
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
Riccardo Danielli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Antibody fusions with immunomodulatory proteins for cancer therapy
Dafne Mueller
PHARMACOLOGY & THERAPEUTICS (2015)
The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer
Teresa Hemmerle et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Emerging classes of armed antibody therapeutics against cancer
Christian Hess et al.
MEDCHEMCOMM (2014)
Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours
G. Spitaleri et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
The Immunocytokine L19-IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
Kathrin Schwager et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma
Francesco Papadia et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity
Stephen D. Gillies
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia
Katrin L. Gutbrodt et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden
Francesca Scrimieri et al.
ONCOIMMUNOLOGY (2013)
Antibody-cytokine fusion proteins
Roland E. Kontermann
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Immunocytokines: a novel class of potent armed antibodies
Nadine Pasche et al.
DRUG DISCOVERY TODAY (2012)
Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery
Kerstin Galler et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2012)
Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention
Richard K. Yang et al.
JOURNAL OF IMMUNOLOGY (2012)
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
Thomas K. Eigentler et al.
CLINICAL CANCER RESEARCH (2011)
Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions
Katharina Frey et al.
EXPERIMENTAL DERMATOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer
Kathrin Schwager et al.
HEAD & NECK ONCOLOGY (2011)
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
Manfred Johannsen et al.
EUROPEAN JOURNAL OF CANCER (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma
Christoph Schliemann et al.
LEUKEMIA RESEARCH (2009)
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo
Alessandra Villa et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The extra-domain a of fibronectin is a vascular marker of solid tumors and Metastases
Jascha-N. Rybak et al.
CANCER RESEARCH (2007)
Characterization of Lewis lung clonal variants in a model of syngeneic pulmonary murine metastases
BT Storey et al.
CLINICAL & EXPERIMENTAL METASTASIS (2004)
Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer
SD Gillies et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
C Halin et al.
NATURE BIOTECHNOLOGY (2002)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
Antibody-cytokine fusion proteins for the therapy of cancer
ML Penichet et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma
M Tanaka et al.
CANCER GENE THERAPY (2000)
Share Paper
